CURE Advisory Committee to The Commons

The CURE Advisory Committee at The Commons brings expertise, advice, and support to the community and also links The Commons’ progress, strategy and planning back to the CURE Board of Directors. This team looks forward to its service as mentors, advisors and contacts available to the companies and entrepreneurs who occupy The Commons.

Susan Froshauer, Ph.D.


Dr. Froshauer is President and CEO of CURE (Connecticut United for Research Excellence, Inc.) and President of CURE Innovations, LLC. She has spent over 27 years in biopharmaceuticals research and development. She is an experienced scientist, pharmaceutical executive, mentor, entrepreneur and angel investor with skill at connecting academic expertise and technology with the commercial sector. Susan is involved with the Yale Entrepreneurial Institute, the CTNEXT funded group, SECT Tech, the Creative Arts Workshop and the Angel Investor Forum. Prior to joining CURE, Dr. Froshauer was Director of the Technology Exchange Portal at the University of Connecticut’s Office of Economic Development. In this role Susan assisted Connecticut-based entrepreneurs and organizations with initiatives that train students, create jobs and contribute to economic development. She connected ideas with business expertise, business plans with investors and industry with scholars.

Until 2010, Susan served as President and CEO of Rib-X Pharmaceuticals, which she co-founded with Yale scientists in New Haven in 2000. Under her leadership, Rib-X raised more than $160 million in private equity, bridge financing and government grants and built an emerging pipeline of antibiotics to treat serious antibiotic-resistant bacterial infections. Prior to Rib-X, for 5 years Susan served as a member of Pfizer’s Strategic Alliance Group where she was part of a team involved in the creation of a $200 million investment portfolio that transformed the Pfizer global research and development strategy, helping the company identify new resources for drug discovery. Prior to work at Pfizer in business development. Dr. Froshauer ran a drug discovery research lab responsible to identify new classes of antibiotics.

Susan received a Ph.D. in Microbiology and Molecular Genetics from Harvard University and a B. A. from Connecticut College. She performed post-doctoral research at Yale Medical School in the Department of Cell Biology as a Jane Coffin Child’s Fellow.

Stanley Choy

stanley-choy-150pxStanley Choy has been a finance executive and business leader for over 20 years both in the pharmaceutical and legal industries. A bioscience entrepreneur, he was most recently Vice President, Finance and Administration of Kolltan Pharmaceuticals. Prior to joining Kolltan in 2009, Mr. Choy was the chief financial officer for a leading Am Law 100 law firm, Edwards Angell, Palmer & Dodge LLP. From 2003-2006, Mr. Choy served as financial controller with Shearman & Sterling LLP, managing the firm’s finance and accounting organization, including fiscal and reporting functions. Prior to joining the legal industry, Mr. Choy spent eleven years at Pfizer Inc., and held several senior finance management positions with Pfizer Pharmaceuticals, Inc., including finance director of business planning for the Consumer Health Care Division, finance director of the Asia & Latin America Region for the Animal Health Care Division, and finance director of the U.S. and Asia Region for the Corporate Finance and Treasurer’s Division. Mr. Choy spent four years at Arthur Andersen & Company in the audit and tax practices early in his career. Stan has an M.B.A. from Syracuse University and is a Certified Public Accountant. He is a member of the American Institute of CPA’s, NYS Society of CPAs, Law Firm CFO Group, and Biotechnology Industry Organization (BIO) Finance and Tax Committee. Mr. Choy currently serves as Co-Chair and Treasurer on the Board of Directors of Connecticut United for Research Excellence (CURE) and as Advisor to The CURE Innovation Commons. Stan also plays a significant role in business development for Bioscience ClubhouseCT.

Peter Farina, Ph.D.

peter-farina-150pxDr. Peter Farina is an Executive in Residence at Canaan Partners, a venture capital firm located in Westport, CT where he assesses and advises on pharma/biotech/healthcare investments. He is also the managing partner of a consulting firm, Salient Science & Technology, LLC which advises several US and Chinese biotech firms on strategic and technical matter in pharmaceutical R&D. Dr. Farina currently serves as the Co-Chair and Board Member of Connecticut United for Research Excellence (CURE); the Advisory Board of the University of Connecticut School of Pharmacy, member of the NIH Blueprint Neurotherapeutics Network (BPN) steering committee; Emory University DRIVE Advisory Board, and was a Founder and CEO of Developing World Cures, a nonprofit company working on neglected diseases. Dr. Farina has a PhD in organic chemistry from SUNY Buffalo and did postdoctoral work in bioorganic chemistry at Pennsylvania State University with Dr. Stephen Benkovic. In May 2014 Dr. Farina was awarded an honorary Doctor of Science degree from the UConn School of Pharmacy for his career accomplishments, leadership in pharmaceutical sciences, and contributions to community and education.

Frank J. Marco, J.D.

frank_marco-150pxFrank Marco is a partner in Wiggin and Dana’s Corporate Practice Department and Chair of the firm’s Private Equity and Emerging Companies Practice Group and Co-Chair of the Clean Technology Practice Group. He has over 30 years of experience in corporate, finance and securities law. His practice focuses on representing venture capital investors and emerging growth companies in capital formation, mergers and acquisitions, public offerings, joint ventures, strategic alliances, licensing, research and development, corporate governance and related matters. He regularly counsels institutional clients on corporate transactions such as mergers and acquisition, spin-offs and corporate ventures. Representative transactions include the sale of a wireless systems company to Cisco Systems, Inc., the sale of a fiberoptics switching company to Sycamore Networks, representing companies in venture capital financings ranging in size up to $100 million, representation of a major financial services company in an equity joint venture, the merger of a client’s oil and gas metering business with Expro Group for $60.5 million and a restructuring and spin-off to the client’s stockholders of its other business lines, and the creation of venture capital investment vehicles. Frank’s experience, which includes six years in the General Counsel’s office of General Electric Company, where he was also General Counsel to General Electric Venture Capital Corporation, gives him a unique background in the venture capital process and in corporate ventures.

Harry H. Penner, Jr., J.D.

pennerHarry Penner is Co-Founder and Executive Chairman of New Haven Pharmaceuticals and has 30+ years of management experience in the pharmaceutical and biotechnology sectors. He has previously co-founded seven other biotechnology companies, including Rib-X Pharmaceuticals, Marinus Pharmaceuticals, Affinimark Technologies, Prevention Pharmaceuticals, RxGen, MAKScientific, and RHEI Pharmaceuticals. From 1993 to 2001, he was President, Chief Executive Officer and Vice Chairman of Neurogen Corporation, a publicly-traded biotechnology company, and from 1985 to 1993, he was Executive Vice President of Novo Nordisk A/S in Denmark and the US. He has also been Chair of the Connecticut Technology Council and Chair of the Connecticut Board of Governors of Higher Education.

Paul Begin

stanley-choy-150pxPaul Begin is Vice President, Real Estate and Facilities Management at Alexion Pharmaceuticals, reporting to the Chief Financial Officer. In his role as Head of Global Real Estate and Facilities Management, Paul provides leadership and oversight across a broad array of functional areas, including Real Estate Strategy and Transactions, Capital Project Management and Construction, Global Facilities Management, Security, Business Continuity Management, and Environmental Health and Safety.

Paul joined Alexion in 2014 to build a world class Real Estate and Facilities Management function for the rapidly growing company.

Prior to joining Alexion, Mr. Begin spent 30 years in similar global roles with companies such as Pfizer, Novartis and most recently with Thomson Reuters. Some of Paul’s key accomplishments include the successful integration of real estate and facilities operations at the diverse sites acquired as part of Pfizer’s strategic merger activities including Warner Lambert, Pharmacia and Wyeth pharmaceutical companies.

Paul graduated from the University of Maryland with a B.S. in Civil Engineering, received his M.B.A. from Rensselaer Polytechnic Institute in 1985 and his Masters in Corporate Real Estate through the CoreNet program in 2009. Paul is a licensed Professional Engineer in the State of Connecticut. He is a proud father of three, and enjoys golf and snowboarding in his time out of the office.

David Wurzer

pennerDave is responsible for managing the investment function at Connecticut Innovations, which includes staffing, portfolio and risk management, outreach, budget planning, and performance measurement. He also is responsible for oversight of the Connecticut Bioscience Innovation Fund (CBIF) and the Regenerative Medicine Research Fund (RMRF).

When he joined CI in 2009 as a senior managing director of investments, Dave had extensive senior-level experience in operations and finance, including more than 10 years as executive vice president, treasurer and CFO of CuraGen Corporation (NASDAQ: CRGN), a former CI portfolio company. Dave guided the biotech company through its initial public offering and helped raise more than $700 million. Dave was also involved in negotiating strategic and business development alliances with several pharmaceutical and biotech companies, including Roche, Bayer and Amgen-Freemont (Abgenix). He helped to grow CuraGen and its technology development subsidiary into an operation with more than 500 employees and a market capitalization as high as $5.3 billion.

Dave began his professional career with Coopers & Lybrand in Hartford, Conn. (now part of PricewaterhouseCoopers), where he held various accounting and managerial positions.